{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Siqueira JM"],"funding":["Salivary Gland Tumor Biorepository","Ryan Smith Adenoid Cystic Carcinoma Fund","Adenoid Cystic Carcinoma Research Foundation","NIDCR NIH HHS","Wold Foundation","U.S. Department of Defense","NCI NIH HHS","DeWayne Everage Adenoid Cystic Carcinoma Fund","Research Histology Core Laboratory"],"pagination":["658-666"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12419983"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["54(8)"],"pubmed_abstract":["<h4>Background</h4>Adenoid cystic carcinoma (ACC) is a common salivary gland carcinoma with high recurrence and distant metastasis rates. Currently, there is no standard systemic treatment available. TROP2 is a transmembrane glycoprotein involved in the oncogenesis of several tumors that can be therapeutically targeted by a TROP2-antibody-drug conjugate (ADC). We aimed to characterize TROP2 expression in ACC and assess TROP2 as a potential therapeutic target.<h4>Methods</h4>TROP2 immunohistochemistry was performed in a tissue microarray including 165 ACC of salivary gland. The tumors were grouped according to the histological pattern as non-solid, solid + non-solid, or solid. TROP2 protein expression in ACC cell lines was assessed and subjected to drug screening with TROP2-ADC.<h4>Results</h4>TROP2 expression was high in 59%, moderate in 30%, weak in 8%, and negative in 3% of cases. TROP2 expression was significantly higher in non-solid compared with solid or solid + non-solid (p < 0.001). Notably, TROP2 expression was heterogenous among the dual cellular component, with TROP2 expression identified predominantly in the ductal and not in the myoepithelial cells. In vitro drug screening demonstrated that TROP2-ADC had selective anti-tumor effect in TROP2 expressing ACC cells.<h4>Conclusions</h4>TROP2 expression is prevalent in ACC, particularly in the ductal cell component of the non-solid tumors. The pre-clinical drug screening findings provide a biological rationale for exploring TROP2 as a therapeutic target in TROP2-expressing ACC.<h4>Trial registration</h4>clinicaltrials.gov: NCT05884320; NCI-2023-04260."],"journal":["Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology"],"pubmed_title":["TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype: Therapeutic Implications."],"pmcid":["PMC12419983"],"funding_grant_id":["W81XWH-21-0409","P30 CA016672","NCI CA16672","HHSN268200900039C","HHSN268200900039C 04"],"pubmed_authors":["El-Naggar AK","Nunes FD","McGrail DJ","Matos LL","de Sousa LG","Spiotto MT","Hanna EY","Siqueira JM","Hoff CO","Mitani M","Ferrarotto R","Carvalho GL","Mitani Y","Marques-Piubelli ML","Bonini F","Lin SY"],"additional_accession":[]},"is_claimable":false,"name":"TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype: Therapeutic Implications.","description":"<h4>Background</h4>Adenoid cystic carcinoma (ACC) is a common salivary gland carcinoma with high recurrence and distant metastasis rates. Currently, there is no standard systemic treatment available. TROP2 is a transmembrane glycoprotein involved in the oncogenesis of several tumors that can be therapeutically targeted by a TROP2-antibody-drug conjugate (ADC). We aimed to characterize TROP2 expression in ACC and assess TROP2 as a potential therapeutic target.<h4>Methods</h4>TROP2 immunohistochemistry was performed in a tissue microarray including 165 ACC of salivary gland. The tumors were grouped according to the histological pattern as non-solid, solid + non-solid, or solid. TROP2 protein expression in ACC cell lines was assessed and subjected to drug screening with TROP2-ADC.<h4>Results</h4>TROP2 expression was high in 59%, moderate in 30%, weak in 8%, and negative in 3% of cases. TROP2 expression was significantly higher in non-solid compared with solid or solid + non-solid (p < 0.001). Notably, TROP2 expression was heterogenous among the dual cellular component, with TROP2 expression identified predominantly in the ductal and not in the myoepithelial cells. In vitro drug screening demonstrated that TROP2-ADC had selective anti-tumor effect in TROP2 expressing ACC cells.<h4>Conclusions</h4>TROP2 expression is prevalent in ACC, particularly in the ductal cell component of the non-solid tumors. The pre-clinical drug screening findings provide a biological rationale for exploring TROP2 as a therapeutic target in TROP2-expressing ACC.<h4>Trial registration</h4>clinicaltrials.gov: NCT05884320; NCI-2023-04260.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-01T13:57:13.227Z","creation":"2026-04-08T13:16:01.283Z"},"accession":"S-EPMC12419983","cross_references":{"pubmed":["40624990"],"doi":["10.1111/jop.70008"]}}